Exosome Biomarkers in Blood, Pancreatic Fluid, and Tissue Samples from Patients with Pancreatic Cancer Undergoing Surgery

PRIMARY OBJECTIVE:

I. Isolate exosomes from the portovenous blood of patients undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy.

SECONDARY OBJECTIVES:

I. Isolate exosomes from peripheral blood, pancreatic duct fluid and the primary pancreatic tumor, if in cancer cohort, in patients undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy.

II. Evaluate liver biopsies in patients undergoing above surgeries for alterations in cellular infiltrate and extracellular matrix protein deposition.

OUTLINE:

Patients undergo collection of blood prior to surgery. Patients also undergo collection of blood and pancreatic duct fluid and a liver biopsy during the laparotomy phase of pancreaticoduodenectomy, partial or complete pancreatectomy, or duodenal ampullectomy. A biopsy of the primary tumor is collected immediately after resection. Exosomes are isolated from peripheral blood, pancreatic duct fluid, and pancreatic tumors via ultracentrifugation with Nanosight. Liver tissue is examined for extracellular matrix (ECM) composition and cellular infiltrate via immunofluorescence (IF) and immunohistochemistry (IHC).

After completion of the study, patients are followed up at 2-4 weeks.